After sinus surgery, it is important to use nasal packing to help control bleeding and provide support to separate tissue and structure at the surgical site. The device comprises bis(hydroxyl)-terminated PLA-PEG-PLA. This device functions to fill nasal/sinus cavities following surgery or trauma and to keep mucosal surfaces separate during the healing process.
Poly(L-lactide-co-ε-caprolactone) | PLCL | CAS No : 65408-67-5 Biodegradable, biocompatible, and bioresorbable copolymer
Biodegradable thermosensitive polymer, poly(dl-lactide-co-glycolide-b-ethylene glycol-b-dl-lactide-co-glycolide) (PLGA-PEG-PLGA) is a desirable ophthalmic drug delivery system because it can be formulated into an injectable solution which forms a gel in situ to provide prolonged drug release.
The hydrogel polymer is an application-tailored PLGA-PEG-PLGA triblock polymer.
The polymer molecule exhibits a hydrophilic core region and hydrophilic ends. An aqueous solution of this polymer is reverse thermosensitive, meaning it is fluid and injectable at room temperature and will rapidly form a hydrogel at body temperature (e.g. after subcutaneous injection).
The polymer is biodegradable due to the instability of ester bonds in the aqueous physiological environment. This process continues at a slow rate and will eliminate the hydrogel from the body in several weeks in a non-toxic way.
Dissolution of PLGA in different solvents depending on the L: G ratio.
The PLGA dissolution depends on the polymer concentration, polymer molecular weight, and temperature. The information is based on a PLGA molecular weight of around 50 kDa and a concentration of 2.5% (w/v) at 37 °C. The PLGAs used were all in the DL form, and most of them have acid end-caps. The end-cap does not appear to affect the solvent solubility. The dark blue indicates solubility.
Poly(D,L-lactide-co-glycolide) | PLGA acid | PLGA-COOH | Nomisma Healthcare
PLGA is a copolymer of lactide and glycolide, which is synthesized by irregular ring-opening polymerization. The degradation rate of PLGA is dependent on the amounts of glycolic acid and lactic acid. The degradation rate of PLGA is dependent on the amounts of glycolic acid and lactic acid. The PLGA containing a higher ratio of lactide is often less hydrophilic than PLGA containing an equal ratio of PLA and PGA or a lower ratio of PLA. This is because the presence of methyl side groups in PLA makes PLA more hydrophobic than PGA, and hence an increased ratio of PLA in PLGA copolymer would ultimately be less hydrophilic, absorb less water, and hence will degrade more slowly. This means that by varying the PLA content or by optimizing the hydrophilic content of PLGA, degradation time can be easily modulated.
The glass transition temperature (Tg) of the PLGA is more than 37°C and hence it is glassy in nature. The good mechanical strength of PLGA can be attributed to the rigid chain structure. The ratio of PLA in PLGA significantly affects the Tg of PLGA. With an increase in the ratio of PLA, Tg increases. Apart from its glassy nature, rigid chain structure, and hydrophilic nature, the physical properties of PLGA also depend on a variety of other factors such as the initial molecular weight, the ratio of lactide to glycolide, the size of the DDS, exposure to water (surface shape) and storage temperature; polydispersity and degree of crystallinity affect the biodegradation of PLGA and its mechanical strength . In the case of crystallinity, the ratio of PLA and PGA plays an important role
Formulation developers are using self-absorbable polymers to create drug delivery systems that improve the patient’s health. Flexibility, convenience and better compliance to meet patient needs can all be incorporated into the system design process involving the use of Proteins, vaccines, and other biological molecules. Scientists can use our polymer to develop & manufacture strategies of controlled release injectable depots, micro/nanoparticles, and solid implants. API together with polymer and solvent is mixed to form a gel which is injected into the patient so that the drug can release as per necessity.
Nomisma Healthcare is one of the world’s leading specialty polymers manufacturer and supplier companies. Serving customers in consumer and industrial markets. The keen, passionate, well-knowledge staff is committed to providing practical, innovative, and elegant solutions to customers in more than 100 countries/regions to meet the complex requirements of various polymers’ grades. We are enthusiastic to learn and implement the growing technology to enhance the process potentials of our customers by providing the choice of product/s of important requirement, without affecting the natural resources which in turn maintain the quality life of human beings. Through the knowledge and applicability – our people, products, and services to the customers across the globe – Nomisma healthcare continues to expand its services with renewable and sustainable solutions.
A key feature of Nomisma healthcare’s bioresorbable polymers is that they contain no detectable residual solvents, reducing concern over potential effects due to solvent/s. Additionally, all bioresorbable polymers meet typical drug and device regulatory thresholds for tin metal levels, established by health authorities, with significantly lower levels than regulatory requirements.